IL17A and COVID-19: In our cohort of hospitalized COVID-19 patients, the activation of Vδ2+ T lymphocytes is inhibited by atorvastatin in a dose-dependent manner, resulting in a significant reduction in the expression of the pro-inflammatory cytokines TNF-α, IFN-γ, and IL-17.